Clinical

Serious adverse events result in Magenta stopping leukemia trial’s high-dose group

A serious adverse event occurred in the phase 1/2 trial of Magenta Therapeutics’ leukemia medicine which resulted in the company having to...

FDA Pushes Back Lynparza Decision to March

The U.S. Food and Drug Administration (FDA) has postponed making a decision on Lynparza for metastatic castration-resistant prostate cancer (mCRPC), which is...

FDA partial hold stands as Avidity shows evidence of the first targeting RNA into muscle

Avidity Biosciences has hinted that the latest phase 1/2 data of the first targeted delivery of RNA into muscle has been successful....

Cytokinetics Set to Make Its Case For Omecamtiv Mecarbil to FDA

Cytokinetics is set to present the benefits of omecamtiv mecarbil - its heart failure drug - to the FDA's advisory committee. However,...

Breyanzi’s case strengthened by Bristol Myers amidst the confrontation with Gilead

A year ago when Breyanzi’s second-line LBCL (large B-cell lymphoma) key data was revealed by Bristol Myers Squibb which found that a...

Sitero And CRIO Join Hands to Streamline Clinical Trial Data

Florida-based CRO Sitero is teaming up with healthcare technology company CRIO to help streamline clinical research for sites and sponsors and enhance...

Dermata’s DMT310 Phase 2 clinical trial for rosacea treatment crashes but shows promising acne treatment results

Dermata Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California. The company specializes in treating medical and aesthetic skin conditions...

Novartis’s radiotherapy Pluvicto succeeds in earlier prostate cancer amidst expansion

Novartis received a clinical data boost which could aid the company’s ambition of $2B in peak sales. Pluvicto proved...

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you

Novartis to combine its pharma and oncology operations to save $1 Billion

Novartis has opted for a corporate restructure...

Pfizer and Flynn Pharma face charges in UK for unfair price hike of epilepsy drug

The U.K.’s competition watchdog claimed that Pfizer...